2 Desember 2020
OUTLINE
Pendahuluan
Tugas dan Fungsi Badan POM dalam Pengawasan
Tahapan Pengembangan Obat
Landasan Hukum Registrasi Obat
Level of Evidence dan Mengapa Uji Klinik untuk pembuktian
keamanan dan khasiat?
Regulasi Uji Klinik di Indonesia
Apakah Uji Klinik selalu menjawab hipotesis yang hendak
dicapai?
Penutup
Tahapan dalam Pengembangan Vaksin
Untuk memastikan vaksin aman dan berkhasiat
Studies in which a
vaccine is given
followed by the
pathogen against
tested in animal small group of given to people given to after vaccine is which the vaccine
studies healthy adult who have thousands of approved and is designed to
volunteers characteristic people licensed protect. Such trials
for efficacy and (age, are uncommon in
safety, physical health) people as they
tested for to monitor AE
including to test for similar to those present
efficacy and and to study
challenge studies safety for whom the considerable
safety long-term effects
new vaccine is ethical challenges.
of the vaccine in
intended
the population
• Permenkes 1120/Menkes/Per/XII/2008
REGISTRASI tentang perubahan atas Permenkes
OBAT 1010/Menkes/Per/XI/2008
Melindungi masyarakat
dari obat dan makanan
Obat yang diedarkan di wilayah Indonesia, yang berisiko terhadap
sebelumnya harus dilakukan registrasi untuk memperoleh Izin kesehatan dengan
Edar. menjamin obat yang
beredar di Indonesia aman,
bermanfaat dan bermutu.
5
Direktorat Registrasi Obat
Badan Pengawas Obat dan Makanan (BPOM)
LEVEL OF EVIDENCE
PEMBUKTIAN
KEAMANAN
DAN KHASIAT
OBAT
Pengembangan Obat Baru MENGAPA UJI KLINIK HARUS
DILAKUKAN ? (1)
Uji Klinik merupakan salah satu
tahapan penting dalam
Pengembangan Obat Baru
(1) In a clinical trial the rights, safety, dignity and well-being of subjects should be protected and the data generated should be
reliable and robust. The interests of the subjects should always take priority over all other interests
(2) In order to allow for independent control as to whether these principles are adhered to, a clinical trial should be subject to
prior authorisation.
MHRA UK
MHRA is regulatory authority responsible for Clinical Trial Authorization, Ovesight and Inspection
US FDA
Clinical trials are an integral part of new product discovery and development, and are generally required by
the Food and Drug Administration (FDA) before a new product can be brought to the market.
All clinical trials of therapeutic products and medicinal products (e.g. Chinese Proprietary Medicines, health
supplements that are being investigated for the treatment or prevention of disease), are regulated by HSA Singapore,
except for observational clinical trials.
PERATURAN KEPALA BADAN POM
NO. 21 TAHUN 2015 TENTANG
TATA LAKSANA PERSETUJUAN UJI KLINIK
ICH E6 (R2)
Good Clinical Practice (GCP) is an international ethical and
scientific quality standard for designing, conducting,
recording and reporting trials that involve the participation
of human subjects. Compliance with this standard provides
public assurance that the rights, safety and well-being of
trial subjects are protected, consistent with the principles
that have their origin in the Declaration of Helsinki, and that
the clinical trial data are credible.
CLINICAL TRIAL PROCESS: Good Clinical Practices
BEFORE DURING AFTER
01 03
Memastikan agar pelaksanaan uji
klinik memenuhi persyaratan Meningkatkan validitas dan
ilmiah, konsep etik (respect to the integritas data hasil uji
klinik 04
person, beneficence, justice) dan
sesuai regulasi yang berlaku.
02
Menghindari risiko yang terjadi Memastikan obat uji klinik
dalam pelaksanaan uji klinik yang digunakan memenuhi
yang dapat mengancam persyaratan mutu
keselamatan subJek
Pasal 4 - 8
KEPUTUSAN
UK Pra-pemasaran:
- Persetujuan
- Penolakan
- Permintaan perbaikan dokumen UK
- Lama waktu: 20 HK, sejak diterimanya dokuen (lengkap)
UK Pasca-pemasaran:
- Tanggapan/respon dalam 20 HK
- Jika dalam 20 HK tidak ada tanggapan dari BPOM, UK dapat dilaksanakan
Note*: Jika pelaksanaan UK lebih dari 2 th, Sponsor atau ORK harus mengajukan permohonan
perpanjangan PPUK, disertai alasan atau justifikasi
PRODUK UJI
(INVESTIGATIONAL PRODUCT)
LINGKUP
NON
MANDATORI
MANDATORI
OBAT
SUPLEMEN KOSMETIKA
KESEHATAN
INSPEKSI UJI KLINIK
25